This review shows the equal or greater importance of leaded gasoline-contaminated dust compared to lead-based paint to the child lead problem, and that soil lead, resulting from leaded gasoline and pulverized lead-based paint, is at least or more important ...
(1) Background: The use of extracorporeal membrane oxygenation (ECMO) in low cardiac output states after cardiac surgery may aid in patient recovery. However, in some patients, the clinical state may worsen, resulting in multiple organ failure and high mortality rates. In these circumstances, calculating a model of end-stage liver disease (MELD) score was shown to determine organ dysfunction and predicting mortality. (2) Methods: We evaluated whether serial MELD score determination increases mortality prediction in patients with postcardiotomy ECMO support. (3) Results: Statistically, a cutoff of a 2.5 MELD score increase within 48 h of ECMO initiation revealed an AUC of 0.722. Further, we found a significant association between hospital mortality and 48 h MELD increase (HR: 2.5, 95% CI: 1.33–4.75, p = 0.005) after adjustment for possible confounders. (4) Conclusions: Therefore, serial MELD score determinations on alternate days may be superior to single measurements in this special patient cohort.
Zusammenfassung Am 25.07.2025 wurde das Update der S3-Leitlinie „Sepsis – Prävention, Diagnose, Therapie und Nachsorge“ veröffentlicht. Die neue Leitlinie adressiert 29 neue und 16 geänderte Empfehlungen, wobei 43 Empfehlungen zur Vorversion unverändert blieben. Das 2025-Update ist eine gezielte Anpassung an die international anerkannten Empfehlungen der Surviving Sepsis Campaign von 2021. Schwerpunkte sind eine frühzeitige, individualisierte und evidenzbasierte Therapie, die Integration strukturierter Nachsorge nach der Krankenhausentlassung und eine stärkere Ausrichtung auf patientenzentrierte Gesamtbetreuung über die akute Behandlung hinaus. Trotz Fortschritten in der Früherkennung, Antibiotikatherapie und intensivmedizinischer Betreuung von Patienten bleiben die Sepsis und der septische Schock potenziell lebensbedrohliche Erkrankungen, was die Notwendigkeit einer frühzeitigen Diagnosestellung und der Einleitung einer bedarfsgerechten Therapie unterstreicht.
OBJECTIVES: The release of neutrophil extracellular traps is a key immune host defense mechanism that can contribute to organ damage during sepsis if excessive. We evaluated presentation H3.1 nucleosome levels in patients with sepsis, septic shock, and sepsis-associated acute kidney injury (AKI). We sought to determine if plasma H3.1 nucleosome levels could serve as predictive biomarkers for both renal replacement therapy (RRT) requirements and 28-day mortality. DESIGN: A secondary analysis of prospectively collected samples from the large multicenter Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients with Severe Sepsis or Septic Shock (SISPCT) trial. SETTING: Patients from 33 ICUs in Germany recruited between November 6, 2009, and June 6, 2013, including a 90-day follow-up period. Patients: A total of 971 patients with complete data on plasma H3.1 admission levels with sepsis and septic shock, and 927 patients with complete data on RRT requirements. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: We evaluated associations between H3.1 levels and mortality and the time to commencement of RRT using multivariable Cox regression. A total of 443 patients (45.6%) presented with sepsis, and 520 patients (53.6%) had septic shock. Admission H3.1 levels were higher in patients with septic shock than sepsis (median, 921.84 vs. 432.71 ng/mL; p < 0.001). In a multivariable analysis for 28-day mortality, a one unit increase in log10 H3.1 levels was associated with a 48% increase in 28-day mortality (adjusted hazard ratio [HR], 1.48, 95% CI, 1.07–2.04; p = 0.02). Plasma H3.1 was also higher in patients with stage 3 AKI requiring RRT with septic shock vs. sepsis (1832 vs. 801.4 ng/mL; p = 0.01). In a multivariable Cox regression controlling for maximum lactate, procalcitonin, and C-reactive protein levels, plasma H3.1 levels were significantly higher in patients who developed AKI requiring RRT when compared with patients who did not develop AKI, with one log10 increase of H3.1 increasing the risk of 28-day RRT by 80% (adjusted HR, 1.8; 95% CI, 1.34–2.40; p < 0.001). CONCLUSIONS: Elevated levels of H3.1 nucleosomes at admission are associated with mortality and AKI requiring RRT. Trial Registration: The trial was registered in clinicaltrials.gov, identifier: NCT00832039.
Background NETosis is a key innate immune defence mechanism where neutrophils release extracellular traps (NETs). However, excessive NET formation may damage organs during sepsis. We investigated the association between NETs and sepsis outcomes, including mortality and acute kidney injury (AKI). Methods We analysed levels of H3.1 nucleosomes in 971 patients with severe sepsis and septic shock from the SISPCT trial (Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock). We evaluated associations between H3.1 levels and mortality and the need for renal replacement therapy using multivariable Cox regression and receiver operating characteristic analyses. Results We analysed 971 critically ill patients with complete data including admission H3.1 levels. 443 patients (45.6%) presented with sepsis, 520 (53.6%) had septic shock, and eight patients had an unknown diagnosis as defined by Sepsis-3. Admission H3.1 levels were higher in patients with septic shock than with sepsis (median 921.84 vs 432.71 ng/mL; p<0.001). Admission H3.1 levels were higher in non-survivors, and in a univariate Cox analysis, each log-10 increase in H3.1 was associated with a hazard ratio of 1.86 (95% confidence interval 1.41–2.47, p<0.05). H3.1 was also higher in patients requiring renal replacement therapy with septic shock vs sepsis (1832 ng/mL vs 801.4 ng/mL, p=0.01) and demonstrated a dose-response relationship with the severity of AKI. Conclusion Elevated levels of H3.1 nucleosomes at admission are independently associated with mortality and severe kidney dysfunction requiring renal replacement therapy. Trial registration Clinicaltrials.gov Identifier, NCT00832039.
Background: The NLRP3 inflammasome is a cytosolic multiprotein complex that serves as a key regulator of innate immunity by reacting to pathogen- and damage-associated signals and orchestrating downstream inflammatory responses. Inflammasome activation induces caspase-1-dependent maturation of interleukin (IL)-1β, IL-18 and gasdermin D, which results in pyroptotic cell death. Main text: While tightly controlled inflammasome activation is essential for effective host defence and pathogen clearance, accumulating evidence implicates its dysregulation as a central driver of host response imbalance in critical illness. In conditions such as sepsis and acute respiratory distress syndrome, excessive activation contributes to hyperinflammation, endothelial dysfunction, immunothrombosis, and multi-organ failure. Conversely, insufficient or exhausted inflammasome responses may impair microbial clearance and predispose to secondary infections. These observations underscore the context-dependent and temporally dynamic role of inflammasome signalling as being either protective or pathogenic. Emerging therapeutic strategies aim to restore immune homeostasis through targeted modulation of inflammasome pathways, including IL-1 blockade (e.g., anakinra) and inhibition of upstream signalling components. However, clinical translation remains challenging, requiring improved patient stratification, biomarker-guided approaches, and a deeper understanding of disease heterogeneity. Conclusions: Inflammasome signalling plays a highly dynamic role in critical illness, contributing to effective host defence, if functional, or to pathological inflammation, if dysregulated. Although targeted modulation of inflammasome pathways represents a promising therapeutic strategy, further research is needed to refine patient selection, identify reliable biomarkers, and better characterise disease heterogeneity to enable successful clinical translation.